Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Pulmatrix, Inc. (PULM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.5500-0.0600 (-1.30%)
At close: 04:00PM EDT
4.5600 +0.01 (+0.22%)
After hours: 06:11PM EDT
Advertisement

Pulmatrix, Inc.

99 Hayden Avenue
Suite 390
Lexington, MA 02421
United States
781 357 2333
https://www.pulmatrix.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees24

Key Executives

NameTitlePayExercisedYear Born
Mr. Teofilo David Raad MBAPres, CEO & Director702.97kN/A1973
Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCDFounder & Member of Scientific Advisory BoardN/AN/A1949
Prof. David A. EdwardsFounder & Member of Scientific Advisory BoardN/AN/A1961
Dr. Alexander M. Klibanov Ph.D.FounderN/AN/A1950
Mr. Peter Ludlum CMA, MBAInterim CFO and Principal Accounting & Financial OfficerN/AN/A1955
Dr. Margaret M. Wasilewski M.D.Chief Medical OfficerN/AN/A1957
Mr. David J. Maki J.D.AdvisorN/AN/A1958
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.

Corporate Governance

Pulmatrix, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement